XenoPort to Present at the 2014 Wells Fargo Healthcare Conference

  XenoPort to Present at the 2014 Wells Fargo Healthcare Conference

Wells Fargo Healthcare Conference 2014

Business Wire

SANTA CLARA, Calif. -- June 9, 2014

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentation at the 2014 Wells Fargo Healthcare
Conference. The live presentation will occur at 11:25 a.m. Pacific Time (2:25
p.m. Eastern Time) on Wednesday, June 18, 2014. A replay of the presentation
will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be
available approximately 24 hours after the live presentation.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets in
the United States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque type psoriasis and/or relapsing forms of
multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release Tablets
is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of
product candidates also includes a potential treatment for patients with
Parkinson's disease.

To learn more about XenoPort, please visit the website at www.XenoPort.com.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.